STAT Plus: TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin
The company has again delayed the readout from its most important blood cancer clinical trial — and the CEO is papering over the very real risk of failure.
.png)
No hay comentarios:
Publicar un comentario